Published on December 8, 2009 at 7:04 AM
Millennium:
The Takeda Oncology Company today reported the presentation of
results from a double randomized Phase III clinical trial of VELCADE
based combinations for the treatment of patients with previously
untreated multiple myeloma (MM). The VELCADE based combinations
evaluated in the study demonstrated two-year overall survival rates
ranging between 81 and 88 percent. The results showed a notable increase
in the rate of complete remissions (CR), which nearly doubled from 23
percent after six cycles of induction to 42 percent after VELCADE based
maintenance treatment. The rigor of double randomization isolates the
impact of VELCADE based maintenance therapy, independent of the
induction regimen. These cooperative group data were generated by the
Spanish Myeloma Group PETHEMA/GEM and presented by Maria-Victoria
Mateos, M.D., Ph.D., Hospital Universitario de Salamanca, Salamanca,
Spain. This presentation was selected for the distinguished plenary
session at the 51st Annual Meeting of the American Society of Hematology
(ASH), held December 5-8, 2009 in New Orleans, Louisiana.
“In this study, VELCADE based combinations delivered impressive two-year
survival rates of up to 88 percent and showed that maintenance regimens
with VELCADE can further improve on the efficacy of VELCADE based
induction therapy after an initial treatment phase of 31 weeks,” said
Dr. Mateos.
“Prolonging overall survival is the primary goal of therapy. We are
extremely pleased by the depth of complete response, the increased
efficacy seen with VELCADE based maintenance, and the impressive overall
survival rates demonstrated in this study,” said Nancy Simonian, M.D.,
Chief Medical Officer, Millennium.
Source Millennium: The Takeda Oncology Company
0dfefec5-1078-4426-b127-f1952acb69c0|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Back Pain, Blindness, Bone, Bronchitis, Cell, Constipation, Cough, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Hematology, Herpes, Herpes Zoster, Hospital, Hypersensitivity, Insomnia, Leukopenia, Liposome, Lymphoma, Lymphopenia, Multiple Myeloma, Myeloma, Nausea, Neuralgia, Neuropathy, Neutropenia, Nursing, Oncology, Peripheral Neuropathy, Pneumonia, Thalidomide, Thrombocytopenia, Vomiting